Squarepoint’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Squarepoint’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-15,700	Closed	-$5K	–	2398
2018 Q2	$5K	Buy	15,700 +4,700	+43%	+$3.85K	﹤0.01%	1712
2018 Q1	$17K	Sell	11,000 -5,600	-34%	-$9.78K	﹤0.01%	1629
2017 Q4	$24K	Buy	+16,600	New	+$27.2K	﹤0.01%	2039
2016 Q3	–	Sell	-47,100	Closed	-$155K	–	1501
2016 Q2	$155K	Buy	+47,100	New	+$178K	0.01%	937

Other funds holding ARLZ

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Squarepoint's ARLZ Position: Q3 2018 in Review

Squarepoint sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 15,700 shares — an estimated $5K sold.

Squarepoint first reported a position in ARLZ in Q2 2016 and held it in 4 quarters. The position peaked at $155K in Q2 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

Squarepoint reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Squarepoint sold 15,700 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $5K.
Squarepoint first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 4 quarters.
Squarepoint's Aralez Pharmaceuticals Inc. position peaked at $155K in Q2 2016.
4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Squarepoint's 13F filing for Q3 2018, filed 14 Nov 2018.